Want to see GB:RTO full AI Analyst Report?
Top Page
Rentokil Initial
(LSE:RTO)
Select Model
Select Model
Rating:62Neutral
Price Target:
372.00 p
▲(6.99% Upside)
Action:Reiterated
Date:08/17/26
The score is supported primarily by solid financial performance (growth and cash generation, with improving leverage) and a constructive earnings update that reaffirmed guidance and showed strong cash conversion. The main drag is weak technicals, with the stock trading below key moving averages and bearish momentum. Valuation is neither clearly cheap nor prohibitive, but the modest yield and ~25x P/E keep it from scoring higher.
Positive Factors
Recurring, route-based contracts
Rentokil’s core business is built on route-based, recurring service contracts across pest control, hygiene and workplace services. This generates predictable, subscription-like revenue, supports higher customer retention and cross-sell, and underpins durable cash flow and margin visibility over time.
Negative Factors
Large termite provisions and claims costs
Material termite provisions and recurring cash settlement costs create an ongoing liability that depresses reported profits and cash flow. Elevated reserve assumptions and continued claim payments represent a structural earnings and cash-flow headwind until exposures are fully resolved or priced into contracts.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring, route-based contracts
Rentokil’s core business is built on route-based, recurring service contracts across pest control, hygiene and workplace services. This generates predictable, subscription-like revenue, supports higher customer retention and cross-sell, and underpins durable cash flow and margin visibility over time.
Read all positive factors
Rentokil Initial (RTO) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£8.33B
Dividend Yield2.87%
Average Volume (3M)14.02M
Price to Earnings (P/E)23.2
Beta (1Y)0.82
Revenue Growth-0.18%
EPS Growth39.04%
CountryUK
Employees63,388
SectorIndustrials
Sector Strength72
IndustrySpecialty Business Services
Share Statistics
EPS (TTM)0.14
Shares Outstanding2,526,039,800
10 Day Avg. Volume11,808,781
30 Day Avg. Volume14,015,040
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)2.76
Price to Sales (P/S)2.20
P/FCF Ratio19.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£497.78Price Target Upside43.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.28
Revenue Forecast (FY)£7.25B
Rentokil Initial Business Overview & Revenue Model
Company Description
Rentokil Initial plc, together with its subsidiaries, provides route-based services in North America, Europe, the United Kingdom, Asia, the Middle East, North Africa, Turkey, and Pacific. The company offers a range of pest control services for rod...
How the Company Makes Money
Rentokil Initial primarily makes money by delivering route-based, recurring-service contracts to business customers. Its core revenue model is built on (1) ongoing service subscriptions/agreements and (2) associated product sales and installation ...
Rentokil Initial Earnings Call Summary
Earnings Call Date:Jul 30, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Mar 04, 2027
Earnings Call Sentiment Positive
The call presented solid financial progress — revenue and operating profit growth, strong cash conversion (96%) and reduced leverage (2.4x) — and clear operational achievements (transformation savings, branch rollout, improved residential performance and regional brand momentum). However, there are meaningful near-term challenges: slower commercial performance, a late-Q2 weakness in residential (termite) leads, higher central costs, increased legacy-termite provisions and elevated one-off transformation cash costs. Management has a detailed remediation plan (sales and operational excellence, customer focus, simplification) and expects steady progress with some initiatives potentially taking up to two years. Overall, the positives on profitability, cash generation and early transformation wins outweigh the stated headwinds, but execution risk on commercial recovery and simplification remains material.Positive Updates
Revenue Growth
Half year revenue increased 4.5% to $3.589 billion with organic revenue growth of 3.6%.
Negative Updates
Commercial Segment Underperformance
Commercial growth lagged overall; although commercial leads grew 8%, conversion and retention declined year-on-year with moderate customer losses in small and midsized accounts (partly due to rationalizing heritage Terminix commercial contracts).
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth
Half year revenue increased 4.5% to $3.589 billion with organic revenue growth of 3.6%.
Read all positive updates
Company Guidance
Management reiterated that full‑year profit is expected in line with market expectations and that the group remains on track for >80% cash conversion (H1 conversion 96%; FCF growth +12.8%), with H1 revenue up 4.5% to $3.589bn (organic +3.6%), operating profit $556m (+6.6%) and an operating margin of 15.5% (+30bps); EPS rose 8.3%. Balance sheet targets include leverage at 2.4x (down 0.4x YoY) now within the 2.0–2.5x target range, net debt down $75m and an interim dividend increase of 8%. The company raised its full‑year cash guidance for one‑off/adjusting items to $110–$120m (H1 cash impact $70m), increased expected cash outflow on the legacy termite provision to $115–$125m, reduced FY M&A spend guidance to $120m, and said central costs (H1 +16.9%) should moderate to low double‑digit growth. Regional detail: North America H1 revenue $2.197bn (+4.2%, organic +3.7%), operating profit $393m (+10.2%) margin 17.9% (+1ppt) (Pest Control margin ~20%, up 1.4% since 2024; residential leads +6%; Business Services +10.6%); transformation delivered $45m gross savings in H1 (net $28m) with ~ $90m annualized run‑rate. International H1 revenue $1.392bn (+5.0%, organic +3.5%), operating profit $266m (+4.3%) margin 19.1%; Q2 international pest organic +5.4% (ex certain businesses +5.8%). Overall, there is no change to the outlook.Rentokil Initial Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
66
Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.11B | 5.13B | 5.44B | 5.38B | 3.71B | 2.95B |
| Gross Profit | 4.41B | 4.26B | 4.56B | 1.50B | 977.00M | 714.80M |
| EBITDA | 1.24B | 1.12B | 1.10B | 1.16B | 747.00M | 676.80M |
| Net Income | 239.80M | 356.63M | 307.00M | 381.00M | 232.00M | 263.00M |
Balance Sheet | ||||||
| Total Assets | 10.97B | 10.73B | 10.55B | 11.13B | 11.92B | 4.32B |
| Cash, Cash Equivalents and Short-Term Investments | 1.86B | 1.73B | 911.00M | 1.56B | 2.09B | 597.90M |
| Total Debt | 4.59B | 4.56B | 4.11B | 4.73B | 5.40B | 1.93B |
| Total Liabilities | 6.81B | 6.65B | 6.33B | 7.04B | 7.82B | 3.06B |
| Stockholders Equity | 4.16B | 4.09B | 4.23B | 4.09B | 4.10B | 1.26B |
Cash Flow | ||||||
| Free Cash Flow | 568.69M | 583.51M | 463.00M | 526.00M | 410.00M | 403.30M |
| Operating Cash Flow | 686.08M | 741.34M | 678.00M | 737.00M | 600.00M | 563.20M |
| Investing Cash Flow | 83.08M | 15.93M | -373.00M | -416.00M | -1.20B | -441.10M |
| Financing Cash Flow | -441.56M | 20.49M | -752.00M | -361.00M | 1.32B | -417.10M |
Rentokil Initial Technical Analysis
Negative
347.70
Price Trends
382.53
Negative
419.44
Negative
434.46
Negative
Market Momentum
-11.78
Negative
26.86
Positive
2.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RTO, the sentiment is Negative. The current price of 347.7 is above the 20-day moving average (MA) of 344.75, below the 50-day MA of 382.53, and below the 200-day MA of 434.46, indicating a bearish trend. The MACD of -11.78 indicates Negative momentum. The RSI at 26.86 is Positive, neither overbought nor oversold. The STOCH value of 2.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:RTO.
Rentokil Initial Risk Analysis
Rentokil Initial disclosed 27 risk factors in its most recent earnings report. Rentokil Initial reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rentokil Initial Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £8.98B | 28.13 | 29.86% | 2.82% | 3.94% | -8.14% | |
65 Neutral | £485.78M | 13.78 | 13.74% | 3.61% | 1.73% | 9.66% | |
65 Neutral | £2.64B | 32.35 | 15.86% | 2.15% | 10.55% | -19.05% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
62 Neutral | £8.33B | 23.22 | 5.82% | 2.87% | -0.18% | 39.04% | |
62 Neutral | £2.42B | 16.15 | 17.55% | 1.87% | 1.20% | 221.80% | |
60 Neutral | £378.68M | 142.18 | 1.30% | 2.30% | 8.11% | -69.68% |
* Industrials Sector Average
GB:RTO
Rentokil Initial
327.70
-38.43
-10.50%
GB:ITRK
Intertek
5,850.00
1,271.20
27.76%
GB:JSG
Johnson Service
133.00
-13.46
-9.19%
GB:MTO
Mitie Group plc
209.00
67.96
48.18%
GB:RST
Restore
300.00
37.18
14.14%
GB:SRP
Serco Group plc
248.20
28.83
13.14%
Rentokil Initial Corporate Events
Business Operations and StrategyExecutive/Board Changes
Rentokil Initial Reshapes Global Structure With New Divisions and Transformation Chief
Positive
Aug 13, 2026
Rentokil Initial is formalising its operating structure into two divisions, North America and International, covering Europe, the UK, Ireland and Sub-Saharan Africa, Asia and MENAT, Latin America and the Pacific. The move is designed to simplify t...
Regulatory Filings and Compliance
Rentokil Initial Executives and Directors Boost Holdings with Coordinated Share Purchases
Positive
Aug 3, 2026
Rentokil Initial reported a series of insider share purchases by senior leadership and board members, including Chief Executive Mike Duffy, who acquired 10,500 American Depositary Shares in a joint account with a closely associated person, and the...
Business Operations and StrategyExecutive/Board ChangesDividendsFinancial Disclosures
Rentokil Initial Sets Growth Platform as Interim Results Show Solid Progress
Positive
Jul 30, 2026
Rentokil Initial reported solid interim performance for the six months to 30 June 2026, with revenue up 6.7%, organic revenue growth of 3.6% and adjusted operating profit rising 6.6%, supported by strong cash generation and a higher dividend. Nort...
Executive/Board Changes
Rentokil Initial Senior Independent Director Joins SSE Board
Positive
Jul 16, 2026
Rentokil Initial said its Senior Independent Director, John Pettigrew, has been appointed as a non-executive director to the board of SSE plc, effective 1 December 2026. The move broadens Pettigrew’s external board responsibilities and may e...
Business Operations and StrategyExecutive/Board Changes
Rentokil Initial Names Rafa Carrasco CEO for North America to Drive Growth
Positive
May 21, 2026
Rentokil Initial has appointed Rafael “Rafa” Carrasco as Chief Executive Officer for its North America business, effective 3 August, bringing in a leader with deep experience in large-scale, route-based service operations and recurring...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.